hat
Rimonabant HCL dwòg se mèsi diferan nan mòd roman li yo nan aksyon kòm yon inik selektif cannabinoid-1 (CB-1) antagonist reseptè. Endocannabinoid yo lage nan CNS yo ak ankouraje lipogenesis, apeti, ak akimans grès nan periferik la. Rimonabant HCL fonksyon yo bloke endokannabinoid efè.
eng
Rimonabant HCL drug is distinct thanks to its novel mode of action as a unique selective cannabinoid-1 (CB-1) receptor antagonist. Endocannabinoids are released in the CNS and stimulate lipogenesis, appetite, and fat accumulation in the periphery. The Rimonabant HCL functions to block endocannabinoids effects.